Biosimilars
Page 1 • 10 itemsTrack global biosimilar approvals, market entry strategies, and regulatory pathways. Gain critical intelligence for your pharmaceutical BD and investment decisions.
Biosimilar Uptake EU: Market Impact Post-Patent Expirations & HTA Regulation
This article examines how biosimilar adoption in the EU is reshaping the market landscape for biologics like Adalimumab after patent expirations and under HTA regulations.
EU Pharmaceutical Legislation Reform: Impact on Generics & Biosimilars 2026-27
The upcoming EU pharmaceutical legislation reform will significantly affect generics and biosimilars, shaping the future of drug access and innovation in 2026-27.
Biosimilar Oncology Antibodies: EMA Market Dynamics & Healthcare Impact
This article delves into the market dynamics of biosimilar oncology antibodies, focusing on their role in cancer treatment and implications for healthcare systems.
Biosimilars Growth in EU: Market Forecast Post-Biologics Patent Expiry
This article analyzes the anticipated growth of biosimilars in the EU following the patent expiry of major biologics, including Humira for rheumatoid arthritis.
![EMA Biosimilar Approvals 2024: Impact on [Specific Drug] Market & Pricing](/uploads/articles/ema-biosimilar-approvals-specific-drug-market-analysis-2024.webp)
EMA Biosimilar Approvals 2024: Impact on [Specific Drug] Market & Pricing
Discover how the 2024 EMA biosimilar approvals will affect the market dynamics and pricing strategies for [Specific Drug] used in treating [Indication].
EU Pharmaceutical Legislation Reform: Impact on Biosimilar Market Access & Competition
The recent EU pharmaceutical legislation reform aims to enhance biosimilar market access and competition, significantly affecting drugs like Adalimumab for autoimmune treatments.
EU Pharmaceutical Legislation Reform: Impact on Generics & Biosimilars 2026-27
The upcoming EU Pharmaceutical Legislation Reform will significantly influence the generics and biosimilars market, affecting drug availability and competition.
EU Pharmaceutical Legislation Impact: Biosimilar Market Entry & Competition 2027
This article examines how upcoming EU pharmaceutical legislation will influence the biosimilar market, focusing on Adalimumab and competition dynamics by 2027.
EU Pharmaceutical Legislation Reform: Impact on Generic and Biosimilar Markets 2026-27
The upcoming EU Pharmaceutical Legislation Reform will significantly reshape the landscape for generic and biosimilar drugs, influencing market dynamics through 2026-27.
EMA Decision on Biosimilar Pricing: Key Insights for Oncology Market
The EMA's recent decision on biosimilar pricing offers crucial insights for the oncology market, influencing drug accessibility and treatment options.